Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept ...

An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early ...

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid ...

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative ...

George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

Teclistamab shows promise for relapsed/refractory multiple myeloma patients with prior BCMA therapy, despite trends of reduced survival and response rates.

Shahzad Raza, MD, discusses the phase 2 RedirecTT-1 study which investigated the combination of talquetamab and teclistamab for treating patients with relapsed/refractory multiple myeloma complicated ...

Researchers explore glioblastoma's genetic complexity using innovative spatial profiling, aiming to enhance treatment ...

Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with ...